PIC Therapeutics is focused on fundamentally changing how we treat cancer based on the modulation of RNA translation in unique ways. Our approach has the potential to become a next generation of cancer therapeutics, simultaneously modulating multiple oncogenic drivers by targeting a key nexus point of cancer signaling pathways.

Worked globally across all Sanofi R&D therapeutic areas with an emphasis on scientific innovation in the internal pipeline and external ecosystem. Created independent and integrative perspectives on important internal and external forces to be considered with regard to prioritization and acceleration of programs that fit strategically with new or existing franchises, investments and development areas.

Built and led Sanofi Sunrise - a venture initiative turning scientific discoveries from outstanding scientists and clinicians into new medicines and treatment paradigms for patients in need. Sought transformative, often high-risk, opportunities to drive innovation by partnering with external life science pioneers and the venture capital community. Strategy enabled a move from the traditional in-license model to a new paradigm of company co-creation and early-stage investing in people and ideas that could transform health care. Through Sunrise, Sanofi changed the R&D model, implementing open innovation at its finest.

o Took over leadership to understand potential breadth of platform for delivering life-saving therapieso Developed a robust data-driven workplan, and reorganized team to execute with urgencyo Ensured critical answers to thesis bearing experiments were obtained as quickly as possibleo Within one year obtained answers needed to save investor’s money and time

o Led a full restart of a Denmark-based biotech under fresh scientific/business leadershipo Raised $38M Series A financing, one of the largest in the 2007-2008 nuclear wintero Led a highly experienced US-based technical team to fully explore robustness of the platformo Identified platform challenges, enabling a pivot under new leadership on remaining Series A runway

o Oversight of La Jolla-based subsidiary discovery and pre-clinical translational researcho Management of key physician relationships to support FDA IND submissiono Managed R&D partnerships and intellectual property portfolio planning and development o Developed key relationships with Members of Congress, DoD and other governmental agencies, ultimately securing funding for critical biodefense research programs

o Following acquisition, led La Jolla-based subsidiary's strategic shift to product development focus and coordination of joint bi-coastal efforts with three pre-clinical programs transitioning toward clinical development

Accomplishmentso Raised seed investment to launch a therapeutic antibody focused start-upo Executed 2 large biopharma partnerships within the first 2 years of launcho Sold company within 3 years to Alexion Pharmaceuticals for a 10X return for investors.